Eurocine Vaccines strengthens the organization for further development
Eurocine Vaccines strengthens the organization with necessary competence, not only to prepare for further development of its first product, the nasal influenza vaccine candidate Immunose™ FLU,Read…
Eurocine Vaccines strengthens the organization for further development
“In parallel with finalizing the analyses and evaluation of the current study, we now prepare for the next steps of development. Reinforcing the organization withRead…
Eurocine Vaccines expects clinical results June/July 2017
Eurocine Vaccines expects results from the ongoing immunological analyses in June/July 2017. The samples presently being analyzed were collected during the clinical study on theRead…
Eurocine Vaccines expects clinical results June/July 2017
“I am pleased that the progress of the immunological analyses has been somewhat faster than expected”, said CSO Dr. Anna-Karin Maltais.”Read More
Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in clinical study
Eurocine Vaccines today announced that Immunose™ FLU, a quadrivalent influenza vaccine candidate showed good safety in a clinical phase I/II study. Immunose™ FLU is a novelRead…
Eurocine Vaccines has completed dosing in phase I/II clinical study with nasal influenza vaccine candidate Immunose™ FLU
Eurocine Vaccines today announced that the last dose has been administered in the ongoing phase I/II clinical study of Immunose™ FLU, a quadrivalent influenza vaccineRead…
Eurocine Vaccines has completed dosing in phase I/II clinical study with nasal influenza vaccine candidate Immunose™ FLU
“The study is conducted at two clinics in Sweden, and we are very pleased with the rapid enrollment,” said Dr. Marie Olliver, Director of Clinical Development.Read…
Eurocine Vaccines announces initiation of clinical study of the nasal influenza vaccine candidate Immunose™ FLU
Eurocine Vaccines today announced the start of a phase I/II clinical study of the quadrivalent influenza vaccine candidate Immunose™ FLU, a novel nose drop formulationRead…
Eurocine Vaccines announces initiation of clinical study of the nasal influenza vaccine candidate Immunose™ FLU
“We are very pleased that our nasal influenza vaccine candidate, Immunose™ FLU, has entered the clinical development stage,” said Dr. Anna-Karin Maltais, Chief Scientific Officer.Read…
The Spirit and Vision of Eurocine Vaccines – Board Directors in Interview
While the team of Eurocine Vaccines is working intensely with the upcoming clinical trial and recently represented the company in Japan, the board directors shareRead…